Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05909995
Other study ID # INCB 99280-205
Secondary ID 2023-503243-34-0
Status Recruiting
Phase Phase 1
First received
Last updated
Start date August 29, 2023
Est. completion date July 27, 2026

Study information

Verified date May 2024
Source Incyte Corporation
Contact Incyte Corporation Call Center (US)
Phone 1.855.463.3463
Email medinfo@incyte.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date July 27, 2026
Est. primary completion date June 27, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Prior systemic therapy, diagnoses and disease setting as follows: - For Part 1 (dose escalation), and no history of treatment with anti-CTLA-4 or anti-PD-(L)1 therapy and one of the following, - Unresectable or metastatic cutaneous melanoma, or - Unresectable of metastatic Child-Pugh Class A NDD not eligible for surgical and/or locoregional therapy, or - Intermediate or poor-risk advanced clear cell RCC, or - MSI-H or dMMR metastatic CRC and able to provide fresh or archival tumor tissue for central confirmation of MSI-H or dMMR. - For Part 2 (dose expansion), IO treatment -naïve, e.g., no prior receipt of an anti PD-1, anti-PD-L1 or PD-L1, anti-CTLA-4, GITR, LAG3, TIM3, OX-40, IL-2, 4-1BB or other immune modulator, and have not received prior systemic therapy and one of the following, - Unresectable or metastatic Child-Pugh Class A HCC not eligible for surgical and/or locoregional therapy, or - Intermediate - or poor-risk advanced clear cell RCC. - ECOG performance score of 0 or 1. - Life expectancy > 3 months, in the opinion of the investigator. - Histologically confirmed solid tumors with measurable disease per RECIST v1.1. - Exception: HCC may be diagnoses based on cross-sectional multiphasic imagining using the AASLD criteria. - Willingness to avoid pregnancy or fathering children. Exclusion Criteria: - Known history of an additional malignancy. - Central nervous system (CNS) metastases requiring treatment and/or leptomeningeal disease. - Toxicity from prior therapy that has not recovered. - Received thoracic radiation within 6 months of the first dose of study treatment. - Participation in another interventional clinical study while receiving INCB099280. - Impaired cardiac function of clinically significant cardiac disease. - History of evidence of interstitial lung disease including non-infections pneumonitis. - Presence of gastrointestinal condition that may affect drug absorption - Any autoimmune disease requiring systemic treatment in the past 5 years. - Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy at a daily dose exceeding 10 mg of prednisone or equivalent - Active infection requiring systemic therapy. - History of organ transplantation, including allogeneic stem cell transplantation. - Receipt of system antibiotics within 28 days of first dose of study treatment. - Probiotic usage is prohibited during the screening and throughout the study treatment period. - Received a live vaccine within 28 days of planned start of study drug. - Laboratory values outside the Protocol-defined ranges. Other protocol-defined Inclusion/Exclusion Criteria may apply.

Study Design


Intervention

Drug:
INCB 99280 with Ipilimumab
Dose Escalation and expansion of INCB 99280 with Ipilimumab

Locations

Country Name City State
Canada McGill University Health Centre/Glen Site/Cedars Cancer Centre Montreal Quebec
Canada Princess Margaret Cancer Center Toronto Ontario
Mexico Hospital Civil de Guadalajara Fray Antonio Alcalde Guadalajara
South Africa Johese Clinical Research: Midstream Centurion
South Africa Mary Potter Oncology Centre Pretoria
United States University of North Carolina At Chapel Hill Chapel Hill North Carolina
United States Henry Ford Health System Detroit Michigan
United States Alliance For Multispecialty Research Llc Knoxville Tennessee
United States Valkyrie Clinical Trials Los Angeles California
United States UC Irvine Medical Center Orange California
United States Sharp Memorial Hospital San Diego California

Sponsors (1)

Lead Sponsor Collaborator
Incyte Corporation

Countries where clinical trial is conducted

United States,  Canada,  Mexico,  South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurence of DLTs 2 Years
Primary Incidence of TEAEs Assessed by physical examinations, changes in vital signs and ECGs, and analysis of clinical laboratory samples. 2 Years
Primary Incidence of TEAEs leading to dose interruption, dose reduction, or discontinuation of either of the study drugs 2 Years
Secondary Concentration of INCB099280 in plasma 2 Years
Secondary Objective response Defined as having a best overall response of complete response or partial response by investigator assessment per RECIST v1.1. 2 Years
Secondary Disease control Defined as having a best overall response of complete response or partial response, or stable disease of = 15 weeks after initiation of study treatment, by investigator assessment per RECIST v1.1. 2 Years
Secondary Duration of Response Defined as the time from the earliest date of CR or PR until the earliest date of disease progression (by investigator assessment per RECIST v1.1) or death due to any cause if occurring sooner than progression. 2 Years
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT03979872 - Risk Information and Skin-cancer Education for Undergraduate Prevention N/A
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Active, not recruiting NCT05470283 - Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma Phase 1
Recruiting NCT05077137 - A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy Phase 1
Active, not recruiting NCT02721459 - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Phase 1
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT05839912 - Excision of Lymph Node Trial (EXCILYNT) (Mel69) N/A
Recruiting NCT04971499 - A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma Phase 1/Phase 2
Recruiting NCT05263453 - HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation Phase 2
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03348891 - TNF in Melanoma Patients Treated With Immunotherapy N/A
Completed NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment Phase 2
Not yet recruiting NCT05539118 - Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma Phase 1/Phase 2
Recruiting NCT05171374 - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Withdrawn NCT02854488 - Yervoy Pregnancy Surveillance Study